Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male, or female of non-child bearing potential; ie, women who are permanently or surgically sterilised or post-menopausal.~* Aged 18 to 80 years inclusive at screening (Visit 1)~* Have a clinical diagnosis of idiopathic or post infective bronchiectasis as diagnosed with a historical high resolution computerised tomography (HRCT) or bronchogram~* Be sputum producers with a history of chronic expectoration on most days of most weeks of the year. Patients should have a history of spontaneously producing sputum on a daily basis and should be able to provide at least 2 of the 3 required baseline sputum samples with an average of 3 mL or more.~* Be on a stable treatment regimen, as judged by the investigator.~Exclusion Criteria:~* Any clinically significant disease or disorder~* Patients with other latent or chronic infections or at risk of infection within 90 days before Visit 2~* An acute exacerbation or acute respiratory infection (upper or lower) requiring oral steroids or antibiotics within 30 days prior to Visit 2~* An FEV1 of \<30% of predicted normal at Visit 1~* Patients who have received live or live-attenuated vaccine in the 2 weeks prior to dosing (Visit 2)~* Concomitant diagnosis of significant pulmonary disease other than bronchiectasis or COPD, including symptomatic asthma and allergic bronchopulmonary aspergillosis~* Bronchiectasis associated with a generalised immunodeficiency disorder, where manifestations other than bronchiectasis predominate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Treatment arm AZD5069
- 2 (Type: PLACEBO_COMPARATOR): Placebo dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).